Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Roche cans muscle-preserving obesity drug, hands it back to Chugai

Summary by endpoints.news
Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with an anti-obesity injectable. The Swiss pharma is stopping work on emugrobart, aptly named GYM329, and is returning ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

BizTocBizToc

Roche Halts Development of Obesity Drug Candidate

The Entire Business World on a Single Page with the Web's Most Comprehensive One-Stop Finance News Hub.

Read Full Article
endpoints.newsendpoints.news

Roche cans muscle-preserving obesity drug, hands it back to Chugai

Roche has scrapped development of a muscle-building drug, ending a trial testing the experimental medicine in combination with an anti-obesity injectable. The Swiss pharma is stopping work on emugrobart, aptly named GYM329, and is returning ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news on Monday, September 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Basel icon

Basel

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal